0.3651
price up icon4.40%   0.0154
after-market 시간 외 거래: 29.72 29.35 +8,040%
loading
전일 마감가:
$0.3497
열려 있는:
$0.3498
하루 거래량:
1.20M
Relative Volume:
0.58
시가총액:
$21.41M
수익:
-
순이익/손실:
$-98.79M
주가수익비율:
-0.1117
EPS:
-3.27
순현금흐름:
$-51.66M
1주 성능:
-43.40%
1개월 성능:
+20.46%
6개월 성능:
-89.54%
1년 성능:
-90.19%
1일 변동 폭
Value
$0.3315
$0.3841
1주일 범위
Value
$0.2675
$0.7409
52주 변동 폭
Value
$0.2404
$4.47

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Name
명칭
Relmada Therapeutics Inc
Name
전화
646 876 3459
Name
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Name
직원
17
Name
트위터
@relmada
Name
다음 수익 날짜
2025-03-25
Name
최신 SEC 제출 서류
Name
RLMD's Discussions on Twitter

RLMD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
3.03 0 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
20.23 372.90M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.1601 355.59M 2.07B -1.42B -1.37B -0.6765
 icon
MOBBW
Mobilicom Limited Warrants
0.2199 318.40M 0 0 0 0.00
 icon
JUNE
Dhandho Junoon Etf
11.50 211.65M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
4.00 156.75M 0 0 0 0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-05 다운그레이드 Mizuho Outperform → Neutral
2024-09-17 업그레이드 Jefferies Hold → Buy
2024-06-05 다운그레이드 Goldman Neutral → Sell
2022-10-14 다운그레이드 Goldman Buy → Neutral
2022-10-14 다운그레이드 Guggenheim Buy → Neutral
2022-10-14 다운그레이드 Truist Buy → Hold
2022-10-13 다운그레이드 Oppenheimer Outperform → Perform
2021-11-18 개시 Mizuho Buy
2021-05-20 재개 Goldman Buy
2020-10-28 다운그레이드 Goldman Buy → Neutral
2020-07-14 개시 Oppenheimer Outperform
2020-05-04 개시 SunTrust Buy
2020-04-21 개시 Goldman Buy
2020-01-27 개시 Jefferies Buy
2020-01-10 개시 SVB Leerink Outperform
2019-12-16 개시 Guggenheim Buy
모두보기

Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스

pulisher
May 02, 2025

Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 01, 2025

Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com

May 01, 2025
pulisher
Apr 30, 2025

It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News

Apr 30, 2025
pulisher
Apr 29, 2025

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News

Apr 29, 2025
pulisher
Apr 29, 2025

Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus

Apr 29, 2025
pulisher
Apr 28, 2025

Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com

Apr 28, 2025
pulisher
Apr 28, 2025

SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

Apr 28, 2025
pulisher
Apr 28, 2025

Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus

Apr 28, 2025
pulisher
Apr 27, 2025

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus

Apr 27, 2025
pulisher
Apr 27, 2025

Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq

Apr 27, 2025
pulisher
Apr 27, 2025

Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan

Apr 27, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 25, 2025

Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX

Apr 25, 2025
pulisher
Apr 24, 2025

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times

Apr 24, 2025
pulisher
Apr 24, 2025

Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News

Apr 24, 2025
pulisher
Apr 23, 2025

RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Relmada Therapeutics Inc (RLMD) receives a Neutral rating from Mizuho - knoxdaily.com

Apr 23, 2025
pulisher
Apr 22, 2025

RLMD Stock: A Comprehensive Analysis and Forecast - investchronicle.com

Apr 22, 2025
pulisher
Apr 18, 2025

Relmada Therapeutics (NASDAQ:RLMD) Trading Down 0.8% – Should You Sell? - Defense World

Apr 18, 2025
pulisher
Apr 14, 2025

Relmada Therapeutics To Present NDV-01 Data at AUA2025 | RLMD St - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025 - TradingView

Apr 14, 2025
pulisher
Apr 14, 2025

Revolutionary Cancer Therapy NDV-01 Data: Game-Changing Results Coming to AUA2025 - Stock Titan

Apr 14, 2025
pulisher
Apr 14, 2025

Relmada Therapeutics To Present NDV-01 Data at AUA2025 - Yahoo Finance

Apr 14, 2025
pulisher
Mar 30, 2025

Relmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone development - MSN

Mar 30, 2025
pulisher
Mar 29, 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025
pulisher
Mar 28, 2025

Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Relmada Therapeutics pivots from psilocybin to cancer, neurological disorders - Crain's Chicago Business

Mar 28, 2025
pulisher
Mar 28, 2025

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... - Yahoo

Mar 28, 2025
pulisher
Mar 28, 2025

Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights - GuruFocus

Mar 28, 2025
pulisher
Mar 27, 2025

Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

RELMADA THERAPEUTICS Earnings Results: $RLMD Reports Quarterly Earnings - Nasdaq

Mar 27, 2025
pulisher
Mar 27, 2025

Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times

Mar 27, 2025
pulisher
Mar 27, 2025

Relmada Cuts Losses by 25%: Key Pipeline Programs Hit Critical Phase in 2025 - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone PharmaSEC Filing - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Insights Ahead: Relmada Therapeutics's Quarterly EarningsRelmada Therapeutics (NASDAQ:RLMD) - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Mizuho maintains Relmada stock neutral with $1.00 target By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - Quantisnow

Mar 26, 2025

Relmada Therapeutics Inc (RLMD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
자본화:     |  볼륨(24시간):